

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Health Technology Evaluation**

**Equality impact assessment – Scoping**

**Tislelizumab with platinum-based chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Stakeholders at scoping raised concerns that there is a socioeconomic influence on incidence of oesophageal cancer and mortality. The age-standardised 5-year survival rate is higher for people in the most deprived quintile compared to people in the least deprived quintile.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will consider all inequalities presented.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made to the scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders related to potential equality issues were identified during scoping.

**Approved by Associate Director (name):** Ian Watson

**Date:** 26 March 2026